Men's Health Month spotlight: Protect your liver

Did you know that liver cancer occurs more frequently in men and is the third-leading cause of cancer-related deaths worldwide?


One major risk factor is chronic hepatitis B infection, often called a “silent” disease because many people infected with the virus experience no symptoms.

The good news?

You can take action.


✅ Learn your risk,

✅ Get tested and

✅ Protect your liver.

Knowledge is power — start here:

Reactivation of Hepatitis B: Understanding Risk Factors & Prevention Strategies

Let’s prioritize men’s health — today and every day.

Join us for the 2025 HBV Community Forum in Berlin or online

The 2025 Hepatitis B Community Forum will be held as a hybrid event on Sept. 8 in Berlin, Germany, just prior to the opening session of the International HBV Meeting. This unique forum brings together scientists, public health professionals and people living with hepatitis B and D to exchange knowledge, share lived experiences and strengthen collaboration in the fight against HBV.


The goal? To foster communication and community engagement that helps drive progress toward a cure and eliminate stigma and discrimination.

Agenda highlights include:

  • Updates on the hepatitis B and Delta treatment landscape in Germany,
  • Epidemiology and progress on HBV elimination, including current challenges
  • Lived experiences of hepatitis B in Europe – interactive panel session and
  • Moderated discussion and open Q&A with audience participation.

Register here for virtual or in-person attendance! There is no cost or fee.


Let’s work together to fast-track a cure and build a world free from HBV-related stigma.

You're Invited: Summer 2025 Hepatitis Delta Connect webinar

Join us for our upcoming Hepatitis Delta Connect webinar, featuring internationally recognized HDV expert Dr. Thomas Vanwolleghem.

Topic: Understanding the long-term health outcomes of hepatitis delta


Dr. Vanwolleghem will share key findings from his research on hepatitis delta virus (HDV), drawing from years of clinical study and patient experience.


  • Tuesday, June 10, 2025
  • 4 p.m. CET / 10 a.m. EDT

Discussion Highlights:

  • Global initiatives from the Hepatitis Delta International Network,
  • The critical need for advocacy to raise awareness and improve HDV education.
  • The importance of increasing access to existing approved treatments.


This is a valuable opportunity to gain insight into the current landscape of hepatitis delta research and advocacy efforts.

New hepatitis B clinical practice guidelines from EASL

The European Association for the Study of the Liver (EASL) officially presented the 2025 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection at the EASL Congress in Amsterdam (May 7–10).


These updated guidelines reflect the latest evidence and expert consensus to support clinicians, researchers and public health professionals in the care and management of hepatitis B. Explore the full guidelines on our website.

The EASL Congress remains Europe’s largest liver-focused scientific gathering, uniting global experts to exchange knowledge, showcase innovation and build collaboration across the hepatology field. Whether you attended in person or joined online, these new guidelines mark a critical advancement in hepatitis B care.

Hep Delta Connect website update

We’re excited to announce recent updates to the Hep Delta Connect website — with fresh enhancements to the Drug Watch and Clinical Trials pages!

  • Drug Watch now includes the latest on emerging therapies for hepatitis D, updated treatment pipelines, and key insights on ongoing drug development.
  • Clinical Trials has been refreshed with new enrollment opportunities, expanded listings, and easier ways to find studies that may be right for patients and providers alike.

Visit Hep Delta Connect and explore what’s new—because staying informed is the first step in advancing care.

Now live: Global job board for hepatitis B, hepatitis D

and liver cancer research opportunities

In response to growing interest from the global hepatitis B community, the Hepatitis B Foundation has launched a dedicated job board featuring opportunities in:

  • Scientific Research,
  • Clinical Studies,
  • Public Health,
  • Policy, Outreach and more.

Post a job opportunity


Submit your announcement using this brief form.


Let’s build the future of liver disease research—one opportunity at a time. Learn more on our website.

Featured #BtheVoice storytellers

  • Alex has lived with hepatitis B for over 50 years. Diagnosed in Houston, he reflects on stigma and encourages others to stay healthy and informed. Alex's story


  • BA, a nurse from Ghana, discovered his status while donating blood. He now leads education and vaccination efforts in rural communities.

BA's story


  • AD from Uganda was diagnosed in 2017. After starting treatment, his viral load became undetectable. He urges others to follow medical guidance. AD's story

This month, we share powerful stories from individuals in Africa and around the world living

 with hepatitis B.

  • Jeremiah from Nigeria learned of his diagnosis during a blood donation. With support from family, he now advocates for early testing. Jeremiah's story


  • Ibrahim faced illness and stigma before being diagnosed. Despite challenges, he stays active and focused on his health. Ibrahim's story
  • After losing her mother, Maryam was screened and diagnosed. With help from a local group, she began treatment and had her children screened.

Maryam's story

Hepatitis B is the leading cause of liver cancer. Early treatment and regular monitoring are key. Visit our storytelling website to check out more stories: www.hepbstories.org.

Hep B United Philadelphia and AFAHO host

community hepatitis B screening

In honor of Hepatitis Awareness Month in May, Hep B United Philadelphia, in partnership with the African Family Health Organization (AFAHO), screened 45 individuals for hepatitis B in Northeast Philadelphia.


Those who require follow-up care will be linked to appropriate services based on their individual needs and test results—ensuring that screening is just the first step toward long-term health.


This was the second screening event with AFAHO this year, and at least one more is planned for the fall as part of our continued commitment to community-based hepatitis B education, prevention and care.

Stay tuned for future updates and opportunities to get involved.

Hepatitis B Foundation highlights patient perspectives

at global workshop on long-acting therapies

Yasmin Ibrahim, MD, PhD, MBA, public health program director at the Hepatitis B Foundation, attended the first International Workshop on Long-Acting Anti-Infectives (LAAI), held May 21–22 in New Orleans.

As the only presenting organization representing the lived experience of those affected by hepatitis B, the Hepatitis B Foundation stood out as one of the few—if not the sole—voices directly advocating on behalf of patients in a space largely dominated by clinical and pharmaceutical viewpoints.


Dr. Ibrahim's presentation shared key insights from a recent global study that explored how people living with hepatitis B perceive long-acting antiviral treatments. Topics included anticipated challenges, community concerns and the critical role of early patient engagement in the development and delivery of new therapies.

Dr. Ibrahim presented on the topic:

“Global perspectives of people living with hepatitis B on long-acting antivirals.”

Key findings included:

  • Strong interest in long-acting treatments but concerns about safety, access and education.
  • Diverse perspectives shaped by geography, healthcare infrastructure and lived experience.
  • The urgent need to incorporate patient voices early in the research and regulatory process.

This participation underscores the Foundation’s ongoing mission to center the voices of people living with hepatitis B in policy, research and treatment innovation conversations.

New hepatitis delta fact sheets available in Amharic

We’re pleased to share that hepatitis delta fact sheets are now available in Amharic! These resources are designed for both patients and health care providers to better understand hepatitis delta, its risks and available treatment options.


Access the fact sheets here. Help spread the word and support informed care in Amharic-speaking communities.

B Heppy Podcast: Hepatitis B treatments in development

In this episode, hosts Bright and Anousha are joined by Dr. Nancy Reau of Rush University to explore the latest developments in hepatitis B treatments.

Dr. Reau shares expert insights on:

  • Promising new therapies in the research pipeline,
  • What these treatments could mean for patients and
  • How the treatment landscape is evolving.


Whether you're living with hepatitis B, working in the field, or simply want to stay informed—this episode is a must-listen.

 Seeking youth & adolescent perspectives on hepatitis B

The Hepatitis B Foundation wants to learn about the experiences of young people living with hepatitis B to improve care and support. We are asking all

youth living with hepatitis B to participate in a brief survey. Their insights will help inform clinicians and health care professionals about the unique needs of youth and adolescents. Sign up here.


Questions? Reach out to Catherine.Freeland@hepb.org

Journal article of the month

Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with

chronic hepatitis B and moderate or high viraemia


The Lancet Gastroenterology and Hepatology


April 2025


Click here to access the abstract


Lim Y-S, Yu M-L, Choi J, Chen C-Y, Choi W-M, Kang W, et al


The authors stress that this study, funded by the Government of South Korea and Gilead Sciences, is "an interim analysis." More than 700 people living with hepatitis B in South Korea and Taiwan participated. The findings, they write, "suggest that earl y treatment with tenofovir alafenamide reduces the risk of liver-related serious adverse events compared with observation in adults with non-cirrhotic chronic hepatitis B and moderate or high viraemia but normal or mildly elevated ALT concentrations. Although these findings await confirmation in planned future analyses, they suggest that existing guidelines could be expanded to allow early antiviral therapy in patients with a moderate or high HBV viral load, irrespective of ALT concentrations."

 

We want to hear from YOU


Please take a moment to complete our reader survey and let us know how we’re doing. Your feedback helps us deliver the content that matters most to you. Take the brief survey here.


Thank you for being a valued part of our community!

Help us make B News even better.
Positive        Neutral        Negative
Learn more about our research and education programs at www.hepb.org

The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public.

Facebook  Twitter  Instagram  Youtube